Key Points
- CEO Robert Blum sold 36,601 shares at an average price of $62.15 for a total of $2,274,752.15, reducing his stake by 7.84% to 430,330 shares.
- Cytokinetics reported Q4 EPS of ($1.50), missing estimates by $0.02, while revenue of $17.76 million beat expectations and rose 4.9% year‑over‑year.
- Analysts are broadly bullish—17 Buys vs. 3 Holds and 1 Sell—with an average price target of $89.89, implying meaningful upside from the current ~ $62 share price and prompting several recent target increases.
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Sung Lee sold 4,935 shares of the business's stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $62.15, for a total transaction of $306,710.25. Following the transaction, the executive vice president directly owned 87,127 shares of the company's stock, valued at $5,414,943.05. The trade was a 5.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Cytokinetics Trading Up 0.1%
Shares of CYTK stock opened at $62.19 on Thursday. Cytokinetics, Incorporated has a 12-month low of $29.31 and a 12-month high of $70.98. The stock has a market capitalization of $7.66 billion, a P/E ratio of -9.52 and a beta of 0.56. The firm's 50 day moving average is $63.80 and its 200 day moving average is $60.94.
Cytokinetics (NASDAQ:CYTK - Get Free Report) last released its quarterly earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.02). The firm had revenue of $17.76 million during the quarter, compared to analysts' expectations of $8.02 million. Cytokinetics's revenue for the quarter was up 4.9% on a year-over-year basis. During the same quarter last year, the firm earned ($1.26) earnings per share. As a group, equities analysts predict that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in Cytokinetics by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 12,048,131 shares of the biopharmaceutical company's stock valued at $765,538,000 after buying an additional 191,336 shares in the last quarter. State Street Corp lifted its holdings in shares of Cytokinetics by 3.7% in the fourth quarter. State Street Corp now owns 5,825,295 shares of the biopharmaceutical company's stock worth $370,139,000 after buying an additional 207,961 shares in the last quarter. Deep Track Capital LP boosted its position in shares of Cytokinetics by 17.8% during the third quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company's stock worth $236,328,000 after acquiring an additional 650,000 shares during the last quarter. Geode Capital Management LLC grew its stake in Cytokinetics by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 3,056,017 shares of the biopharmaceutical company's stock valued at $194,214,000 after acquiring an additional 15,815 shares in the last quarter. Finally, Vestal Point Capital LP lifted its stake in Cytokinetics by 14.8% in the 2nd quarter. Vestal Point Capital LP now owns 2,975,000 shares of the biopharmaceutical company's stock worth $98,294,000 after purchasing an additional 384,469 shares in the last quarter.
Analysts Set New Price Targets
Several brokerages have issued reports on CYTK. Leerink Partners reissued an "outperform" rating on shares of Cytokinetics in a research report on Tuesday, March 10th. Citigroup reaffirmed a "market outperform" rating on shares of Cytokinetics in a research report on Monday, December 22nd. Barclays began coverage on shares of Cytokinetics in a report on Wednesday, January 28th. They issued an "overweight" rating and a $87.00 price objective on the stock. The Goldman Sachs Group set a $95.00 target price on shares of Cytokinetics and gave the company a "buy" rating in a research report on Thursday, December 18th. Finally, Citizens Jmp upped their target price on shares of Cytokinetics from $88.00 to $96.00 and gave the company a "market outperform" rating in a report on Wednesday, February 25th. Seventeen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $89.89.
Get Our Latest Analysis on Cytokinetics
Trending Headlines about Cytokinetics
Here are the key news stories impacting Cytokinetics this week:
- Positive Sentiment: JPMorgan raised its price target on CYTK from $74 to $75 and kept an overweight rating, providing additional analyst support for the stock. JPMorgan Boosts Cytokinetics Price Target to $75.00
- Positive Sentiment: Mizuho raised its price target to $100 and reiterated an outperform view, representing material upside vs. the current share price and likely attracting momentum buying. Mizuho Raises Price Target to $100
- Positive Sentiment: Barclays kept a buy rating on CYTK, which reinforces analyst demand-side support from multiple firms. Barclays Keeps Their Buy Rating on Cytokinetics
- Neutral Sentiment: Cytokinetics granted inducement awards (8,628 stock options and 5,719 RSUs) to five recent hires under Nasdaq Rule 5635(c)(4). This is standard hiring compensation; it could cause modest dilution over time but is aimed at talent acquisition. Cytokinetics Announces Inducement Grants
- Negative Sentiment: Several insiders sold sizable positions this week — including CEO Robert I. Blum (36,601 shares) and multiple EVPs — totaling multimillion‑dollar transactions. Insider selling can create near‑term selling pressure or be viewed as portfolio diversification; filings are available with the SEC. Form 4 — CEO Insider Sale
About Cytokinetics
(
Get Free Report)
Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.
The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
